Benralizumab

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody medication which is developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[2][3] Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.[4][5] It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe e... [wikipedia]